Phenotypic profiling of solute carriers characterizes serine transport in cancer.

"Competing interests Cancer Research Technology owns a patent filing relating to SLC inhibition. O.D.K.M. is a co-founder, shareholder and board member of Faeth Therapeutics and contributed to the CRUK Cancer Research Technology filing of patent application WO/2017/144877. K.H.V. is on the board of directors and shareholder of Bristol Myers Squibb and on the science advisory board (with stock options) of PMV Pharma, RAZE Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the scientific advisory board of Ludwig Cancer and is a co-founder and shareholder of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to the CRUK Cancer Research Technology filing of patent application WO/2017/144877. The other authors declare no competing interests."

"We thank Biological Services facility staff at the Cancer Research UK (CRUK) Beatson Institute, funded by CRUK (A18076, A17196 and A31287). We also thank the following: P. A. Gammage for advice regarding mitochondrial fractionation for protein analysis; D. A. Tennant for sharing his protocol of cellular compartmentalization and GC–MS analysis; J. Macrae and the Metabolomics STP of the Francis Crick Institute; M. Howell and the High-Throughput Screening STP of the Francis Crick Institute and the Advanced Light Microscopy STP of the Francis Crick Institute. V.P., A.H.U., A.C.N., T.Z. and O.D.K.M. were funded by a CRUK Career Development Fellowship awarded to O.D.K.M. (C53309/A19702). M.F. was funded by an EMBO Long-Term Fellowship (EMBO ALTF 276-2019). K.B. and D.A. were core funded by CRUK (A17196, A29799 and A31287). L.M. and E.S. were core funded by CRUK (A17196). K.H.V. is supported by the Francis Crick Institute, which receives its core funding from CRUK (CC2073), the UK Medical Research Council (CC2073) and the Wellcome Trust (CC2073)."